Filing Flows › Tvardi Therapeutics (TVRD) › Q1 2025
Tvardi Therapeutics (TVRD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Tvardi Therapeutics (TVRD) reported revenue of $2.6M for the first quarter 2025 (Q1 2025), +20% from a year earlier and +77% from the quarter before. Operating margin was -92.9%, net loss $4.9M (191.0% of revenue).
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.6M | +77% | +20% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$4.9M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $2.6M in Q1 2025, up 20% year over year and up 77% from the previous quarter. Other revenue was the largest line at 51% of revenue. Other revenue added $700K year over year (up 112%), 161% of the total change. Clinical compound revenue declined 43%.
Operating costs exceeded revenue by $2.4M, an operating margin of -92.9%. Total costs fell 84% while revenue rose 20%. The quarter ended with a net loss of $4.9M, narrower than the previous quarter's $7.7M loss. Net interest and other expense of $2.5M was the main reason.
Operating cash flow was −$4.7M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $1.2M.
Questions
What was Tvardi Therapeutics' revenue in the first quarter 2025?
Tvardi Therapeutics (TVRD) reported revenue of $2.6M for the first quarter 2025 (Q1 2025), +20% from a year earlier and +77% from the quarter before.
Was Tvardi Therapeutics profitable in the first quarter 2025?
Operating loss was $2.4M (-92.9% of revenue) and net loss $4.9M.